- Home
- PBYI vs ENX Comparison
PBYI vs ENX Comparison
Compare PBYI & ENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- ENX
- Stock Information
- Founded
- PBYI 2010
- ENX 2002
- Country
- PBYI United States
- ENX United States
- Employees
- PBYI N/A
- ENX N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- ENX Finance/Investors Services
- Sector
- PBYI Health Care
- ENX Finance
- Exchange
- PBYI Nasdaq
- ENX Nasdaq
- Market Cap
- PBYI 153.2M
- ENX 175.5M
- IPO Year
- PBYI N/A
- ENX N/A
- Fundamental
- Price
- PBYI $3.09
- ENX $9.48
- Analyst Decision
- PBYI Strong Buy
- ENX
- Analyst Count
- PBYI 1
- ENX 0
- Target Price
- PBYI $7.00
- ENX N/A
- AVG Volume (30 Days)
- PBYI 754.5K
- ENX 25.4K
- Earning Date
- PBYI 02-27-2025
- ENX 01-01-0001
- Dividend Yield
- PBYI N/A
- ENX 3.94%
- EPS Growth
- PBYI 492.79
- ENX N/A
- EPS
- PBYI 0.47
- ENX 0.16
- Revenue
- PBYI $243,569,000.00
- ENX N/A
- Revenue This Year
- PBYI N/A
- ENX N/A
- Revenue Next Year
- PBYI N/A
- ENX N/A
- P/E Ratio
- PBYI $6.63
- ENX $61.00
- Revenue Growth
- PBYI 6.30
- ENX N/A
- 52 Week Low
- PBYI $2.23
- ENX $7.84
- 52 Week High
- PBYI $7.73
- ENX $10.07
- Technical
- Relative Strength Index (RSI)
- PBYI 49.17
- ENX 41.09
- Support Level
- PBYI $2.92
- ENX $9.42
- Resistance Level
- PBYI $4.06
- ENX $9.89
- Average True Range (ATR)
- PBYI 0.29
- ENX 0.12
- MACD
- PBYI 0.01
- ENX -0.01
- Stochastic Oscillator
- PBYI 27.07
- ENX 29.35
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.